Trevi Therapeutics, Inc. Common Stock
Symbol: TRVI (NASDAQ)
9.49
▲ (12.76%) 1.074
Company Description:
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Key Stats
- Today's Open: $8.42
- Today's High: $9.544
- Today's Low: $8.346
- Today's Volume: 4.22M
- Yesterday Close: $8.42
- Yesterday High: $8.63
- Yesterday Low: $7.44
- Yesterday Volume: 5.81M
- Last Min Volume: 1.39K
- Last Min High: $9.452
- Last Min Low: $9.45
- Last Min VWAP: $9.45019
Company Profile
- Name: Trevi Therapeutics, Inc. Common Stock
- Website: https://www.trevitherapeutics.com
- Listed Date: 2019-05-03
- Location: NEW HAVEN, CT
- Market Status: Active
- CIK Number: 0001563880
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $925.50M
- Round Lot: 100
- Outstanding Shares: 121.78M
- Asset Type: CS
RECENT FILINGS FOR TRVI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-27 | 144 | View |
| 2025-08-20 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-11 | SCHEDULE 13D/A | View |
| 2025-08-07 | S-8 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-09 | SCHEDULE 13G | View |
| 2025-06-17 | 8-K | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-04 | 8-K | View |
| 2025-06-04 | 424B5 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
Latest News on TRVI